Literature DB >> 34356770

Synergy between Phage Sb-1 and Oxacillin against Methicillin-Resistant Staphylococcus aureus.

Kevin Simon1, Wolfgang Pier1, Alex Krüttgen2, Hans-Peter Horz1.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a notorious pathogen responsible for not only a number of difficult-to-treat hospital-acquired infections, but also for infections that are community- or livestock-acquired. The increasing lack of efficient antibiotics has renewed the interest in lytic bacteriophages (briefly phages) as additional antimicrobials against multi-drug resistant bacteria, including MRSA. The aim of this study was to test the hypothesis that a combination of the well-known and strictly lytic S. aureus phage Sb-1 and oxacillin, which as sole agent is ineffective against MRSA, exerts a significantly stronger bacterial reduction than either antimicrobial alone. Eighteen different MRSA isolates and, for comparison, five MSSA and four reference strains were included in this study. The bacteria were challenged with a combination of varying dosages of the phage and the antibiotic in liquid medium using five different antibiotic levels and four different viral titers (i.e., multiplicity of infections (MOIs) ranging from 10-5 to 10). The dynamics of the cell density changes were determined via time-kill assays over 16 h. Positive interactions between both antimicrobials in the form of facilitation, additive effects, or synergism were observed for most S. aureus isolates. These enhanced antibacterial effects were robust with phage MOIs of 10-1 and 10 irrespective of the antibiotic concentrations, ranging from 5 to 100 µg/mL. Neutral effects between both antimicrobials were seen only with few isolates. Importantly, antagonism was a rare exception. As a conclusion, phage Sb-1 and oxacillin constitute a robust heterologous antimicrobial pair which extends the efficacy of a phage-only approach for controlling MRSA.

Entities:  

Keywords:  MRSA bacteriophage; Staphylococcus aureus; oxacillin; synergy

Year:  2021        PMID: 34356770     DOI: 10.3390/antibiotics10070849

Source DB:  PubMed          Journal:  Antibiotics (Basel)        ISSN: 2079-6382


  5 in total

1.  Phage Activity against Planktonic and Biofilm Staphylococcus aureus Periprosthetic Joint Infection Isolates.

Authors:  Katherine M C Totten; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.938

Review 2.  Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far.

Authors:  Marzanna Łusiak-Szelachowska; Ryszard Międzybrodzki; Zuzanna Drulis-Kawa; Kathryn Cater; Petar Knežević; Cyprian Winogradow; Karolina Amaro; Ewa Jończyk-Matysiak; Beata Weber-Dąbrowska; Justyna Rękas; Andrzej Górski
Journal:  J Biomed Sci       Date:  2022-03-30       Impact factor: 8.410

3.  Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections In Vitro: Bacteriophage-Antibiotic Combination.

Authors:  Razieh Kebriaei; Katherine L Lev; Rahi M Shah; Kyle C Stamper; Dana J Holger; Taylor Morrisette; Ashlan J Kunz Coyne; Susan M Lehman; Michael J Rybak
Journal:  Microbiol Spectr       Date:  2022-03-29

4.  An Optimized Checkerboard Method for Phage-Antibiotic Synergy Detection.

Authors:  Isidora Nikolic; Darija Vukovic; Damir Gavric; Jelena Cvetanovic; Verica Aleksic Sabo; Sonja Gostimirovic; Jelena Narancic; Petar Knezevic
Journal:  Viruses       Date:  2022-07-14       Impact factor: 5.818

5.  Bacteriophages Combined With Subtherapeutic Doses of Flucloxacillin Act Synergistically Against Staphylococcus aureus Experimental Infective Endocarditis.

Authors:  Jonathan Save; Yok-Ai Que; José M Entenza; Camille Kolenda; Frédéric Laurent; Grégory Resch
Journal:  J Am Heart Assoc       Date:  2022-01-19       Impact factor: 6.106

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.